Q3: continued sales and earnings progress Paris, October 24, 2025 Q3 sales growth of 7.0% at CER1 and business earnings per share (EPS)2 of €2.91 Pharma launches increased sales by 57.1%, reaching €1.0 billion, driven by ALTUVIIIO and Ayvakit Dupixent sales increased by 26.2% to €4.2 billion, first time above €4 billion in a quarter Vaccines sales decreased by 7.8% to €3.4 billion, from lower influenza sales Research and Development expenses were €1.8 billion, an increase of 4.9% Selling, general and admin ...